Lead Product(s) : BI 1467335,Inapplicable
Therapeutic Area : Sleep
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
June 15, 2023
Lead Product(s) : BI 1467335,Inapplicable
Therapeutic Area : Sleep
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : BI 1467335,Inapplicable
Therapeutic Area : Ophthalmology
Study Phase : Phase II
Sponsor : Pharmaxis
Deal Size : Inapplicable
Deal Type : Inapplicable
Boehringer Ingelheim Discontinues Development of BI 467335 for Diabetic Retinopathy
Details : Boehringer Ingelheim decided not to further develop BI 1467335 in this indication based on the lack of a clear efficacy signal and risk of dose dependent drug interactions of the compound in NPDR patients identified in another Phase I study.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 09, 2020
Lead Product(s) : BI 1467335,Inapplicable
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II
Sponsor : Pharmaxis
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : BI 1467335,Tyramine
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study in Healthy People to Test How Combining BI 1467335 and Tyramine Affects Blood Pressure
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 07, 2019
Lead Product(s) : BI 1467335,Tyramine
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : BI 1467335,Inapplicable
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 25, 2019
Lead Product(s) : BI 1467335,Inapplicable
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : BI 1467335,14-C BI 1467335
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
This Study in Healthy Men Tests How the Body Takes up BI 1467335
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 30, 2018
Lead Product(s) : BI 1467335,14-C BI 1467335
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : 14-C BI 1467335,BI 1467335
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Radiolabeled Compounds
Upfront Cash : Inapplicable
December 26, 2017
Lead Product(s) : 14-C BI 1467335,BI 1467335
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : BI 1467335,Inapplicable
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 18, 2017
Lead Product(s) : BI 1467335,Inapplicable
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : BI 1467335,Inapplicable
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 21, 2016
Lead Product(s) : BI 1467335,Inapplicable
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : BI 1467335,Inapplicable
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 11, 2016
Lead Product(s) : BI 1467335,Inapplicable
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable